Exosome Therapy vs LLLT (Laser Light Therapy) for Hair Loss: An Honest Comparison
Low-level laser therapy, usually shortened to LLLT, is one of the older non-surgical hair loss treatments: the first device was FDA-cleared in 2007, and the technology has been studied in clinical trials for longer than most of the alternatives people now compare it against.
It is also one of the most confusing to research, because the same technology gets sold under at least three different names (“LLLT,” “photobiomodulation,” “red light therapy”), delivered in two completely different settings (at-home devices and clinical sessions), and lumped together with consumer LED panels that are not the same thing.
Book your consultation
LLLT uses specific wavelengths of red or near-infrared laser light to stimulate follicles.
"Red light therapy" is a consumer wellness term and many do not meet paremetrs needed to affect hair growth
The most practical difference is where treatment happens: LLLT is largely a home-device commitment; exosome therapy is clinic-based
LLLT vs. Exosomes: The Short Answer
LLLT has a more developed evidence base than exosome therapy, and the evidence it has is reasonably strong: a 2024 head-to-head trial found LLLT comparable to minoxidil in hair density improvements over six months, and a 2025 meta-analysis across 38 studies found significant benefit over sham.
Exosome therapy is newer, with a smaller but encouraging body of evidence. The studies that exist report density improvements in a similar range to LLLT, but there are fewer of them and they are shorter in follow-up.
The practical difference between the two is as important as the evidence difference. LLLT is usually purchased as a device and used at home, on a consistent schedule, for years. Exosome therapy is a course of clinic sessions. For many people, that distinction decides the choice before the evidence comparison even comes into it.
| LLLT | Exosome therapy (Hair Revive protocol) | |
|---|---|---|
| What it is | Calibrated red/near-infrared laser light, delivered to the scalp | Signalling vesicles from a salmon-derived laboratory preparation |
| How it works | Stimulates mitochondria in follicle cells, increasing cellular energy and shifting follicles into the growth phase | Delivers growth factors and microRNA to struggling follicles via topical application with microneedling |
| Evidence base | Strong: 2025 meta-analysis of 38 studies (3,098 patients); FDA clearances since 2007 | Emerging: 2025 systematic review of 11 studies, 2 RCTs |
| NICE / NHS | Not NICE-recommended or NHS-provided | Not NICE-recommended or NHS-provided |
| UK regulatory status | CE/UKCA-marked medical devices; Class IIa. No NICE guidance; not NHS-funded | Unlicensed ATMP category; Hair Revive protocol sits outside the MHRA's specific injection and human-biologicals concerns |
| Where you receive it | Mainly at home (purchased device); also available in some clinics | CQC-registered clinic under GMC-registered medical oversight |
| Session commitment | 15 to 30 minutes, every other day or 3 times per week, ongoing indefinitely | 3 to 6 clinic sessions, spaced 4 to 6 weeks apart, then maintenance |
| Side effects | Temporary shedding in first 1 to 2 months; mild scalp itch; headaches (rare) | Mild scalp redness; transient sensitivity at treatment sites |
What Is LLLT?
LLLT uses specific wavelengths of non-thermal laser light to stimulate cells. When applied to the scalp, the light is absorbed by mitochondria inside follicle cells, which triggers increased energy production and a cascade of effects that encourage dormant or miniaturising follicles back into the active growth phase.
"Low-level laser therapy," "photobiomodulation," and "laser phototherapy" all refer to the same thing. The preferred clinical term is now photobiomodulation (PBM), but LLLT remains the most commonly searched consumer term in the UK, so both are used throughout this page.
Red light therapy: related but not the same
"Red light therapy" (RLT) is a consumer wellness umbrella term applied to a wide range of LED panels, handheld devices, and face masks. Some of those products deliver light in the right wavelength range and at the right dose to stimulate follicles. Many do not. The problem is that consumer RLT products are not required to specify their wavelength, power output, or fluence, and most have no hair-specific clinical evidence behind them.
When this article refers to LLLT, it means devices that deliver calibrated light in the 630 to 670 nm (red) or 800 to 900 nm (near-infrared) range, at a dose known as "fluence" of roughly 2 to 4 joules per centimetre squared. That is the specification that the evidence was built on, and it is what the FDA-cleared devices are designed to deliver.
How it works
Light Energy Enters & Releases NO
Cell Is Able to Generate More ATP
Hair Grows Back Thicker as a Result
Each hair follicle contains mitochondria, the cell's energy-producing structures. An enzyme inside the mitochondria called cytochrome c oxidase absorbs light in the red and near-infrared range, which releases a natural inhibitor (nitric oxide) and allows the mitochondria to produce more ATP, the cell's main energy source.
More energy in the follicle cell translates to increased cellular activity: follicles are nudged out of the resting (telogen) phase, the active growth (anagen) phase is prolonged, and the signalling pathways that support follicle health (including Wnt/beta-catenin, which is also targeted by exosome therapy) are upregulated. The result, in theory, is that miniaturising follicles start producing thicker hairs and shed less readily.
One important nuance: there is a biphasic dose response. Too little light does nothing; the right dose stimulates; too much light can actually inhibit follicle activity. This is one reason poorly calibrated or very cheap devices may not produce results, and why devices with defined power outputs are preferable to generic "red light" products.
Clinical vs home delivery
LLLT is delivered either in a clinic, using dedicated laser panels or hoods, or at home using a device you purchase. The home device category includes laser combs and brushes (such as the HairMax LaserBand, typically 7 to 82 diodes), laser helmets and caps (such as iRestore and Capillus, typically 51 to 272 diodes), and a growing number of LED-only caps without laser diodes.
Most of the published clinical evidence was actually generated using home-use devices rather than clinic equipment, which means the RCT evidence base is directly applicable to at-home use. Laser-diode devices have a stronger evidence base than LED-only devices: a 2022 meta-analysis of FDA-cleared home devices found a significantly higher effect size for laser-diode-only devices compared to laser/LED combinations.
What Is Exosome Therapy for Hair Loss?
Exosomes are tiny signalling parcels released by cells, packed with growth factors, microRNA and other molecules.
Exosome therapy for hair loss delivers a concentrated preparation of these parcels to the scalp, with the aim of prompting struggling follicles to function better.
At Hair Revive we use the E50 Exosome preparation, which is salmon-derived, and we deliver it topically with microneedling and TargetCool, not by injection.
Home Treatment vs Clinic Treatments
This is the most practically important distinction between LLLT and exosome therapy, and it often determines the choice before the evidence is even weighed.
LLLT
A device you own and use at home
Once you have purchased a suitable device, LLLT has no ongoing per-session cost. You use it at home on a defined schedule (typically twenty minutes every other day or three times per week), and the commitment extends indefinitely. The device is yours to use for as long as it works.
Purchase Device
Follow Strict Schedule
Continue Indefinitely
The trade-off is adherence. Consistent, long-term compliance is required. Sessions are easy, but doing them reliably for months and years is a different kind of commitment from attending a clinic course. A 2025 review found that the strongest results in LLLT trials came from treatment programmes longer than twenty weeks, suggesting that the benefits build with sustained use rather than arriving quickly.
Exosomes
A structured Clinical Course
Exosome therapy requires you to attend a clinic. Sessions are spaced four to six weeks apart and take around forty-five minutes each. There is no home-use component. The commitment is front-loaded in time and cost compared to LLLT, and the clinical setting means professional oversight at every session.
Attend Clinic
Periodically Return
Conclude When Advised
For patients who prefer to have treatment managed by a clinical team and reviewed as they go, rather than self-managing a home device, the clinic-based model has a practical advantage independent of the evidence comparison.
LLLT vs. Exosomes: What the Research Shows
Both treatments aim at the same biological target: supporting the dermal papilla, extending the growth phase, and encouraging miniaturising follicles to produce thicker hair. They approach it with different raw materials, and the difference is worth understanding.
LLLT
A substantial and growing evidence base
LLLT has been studied in controlled trials for pattern hair loss since the early 2000s.
A 2025 meta-analysis in Dermatologic Surgery across 38 studies and 3,098 patients (94% with androgenetic alopecia) found significant hair density improvement over sham for both short and longer treatment durations, with an effect size (SMD) of 1.44 for programmes longer than twenty weeks.
A 2022 meta-analysis of FDA-cleared home devices covering 7 RCTs and 607 participants found an overall standardised mean difference of 1.27 for hair density, with specific device results including a 63.7% improvement vs 12.5% for sham in one trial and a 35 to 37% increase in hair counts in another.
"LLLT is a promising treatment option for patients with androgenetic alopecia, but future studies are needed to better understand its efficacy in other alopecia types."
A 2024 head-to-head RCT comparing LLLT directly with 5% topical minoxidil in 91 men over six months found no statistically significant difference between the two: both treatments significantly improved hair density from baseline, and clinical responder rates were 72.9% for LLLT vs 81.5% for minoxidil. For patients who have found minoxidil difficult to tolerate or sustain, this is clinically meaningful.
The evidence is not without limitations. Heterogeneity across trials is high, driven by variation in device type, wavelength, dosing, and study duration. European dermatology guidelines rate the evidence at Level 2 (low to moderate quality). These are the same honest caveats that apply to most non-surgical hair loss treatments.
Exosomes
Promising Early Evidence
"A statistically significant difference was seen in the answers given in the 12th week compared to the 4th week (p < 0.05).
According to the patients’ answers in the 4th week, a positive change was observed in all but five patients in the 12th week."
Exosome therapy has a smaller but encouraging evidence base. A 2025 systematic review in Clinical, Cosmetic and Investigational Dermatology covering eleven clinical studies (including two RCTs) found density increases of 9.5 to 35 hairs per cm² across the exosome studies, with mild and transient adverse events only.
The reviewers are explicit that the studies are small and follow-up is short. The honest comparison with LLLT is that both show similar density improvement ranges in their respective study populations, but LLLT has far more studies, a longer track record, and regulatory clearance in major markets. Exosome therapy has newer and more limited evidence.
Exosomes
Our Experience at Hair Revive
We began offering E50 Treatment to our clinic in early 2025.
The pattern we see in practice is broadly consistent with what the wider exosome literature reports: where patients have early-to-mid-stage pattern hair loss and follicles are still present, many go on to see improvements in density and hair condition over the course of treatment.
In cases where follicles are no longer active or the hair loss is advanced, the response is limited, which is why we assess every patient before agreeing a course.
This is clinical observation from practice, not a published audit, and we describe it that way. It informs how we approach patient selection and contributes to our confidence in the protocol. It is not a substitute for peer-reviewed evidence, and we are not presenting it as such.
Clinical Observations at The Hair Revive Clinic
We've proudly offered E50-H Treatment for over a year in our Clinic and tracked our own visitors progress over time.
Visit our Results Page to some of the transformations we've achieved:
VISITOR RESULTS →
Can They Be Used Together?
There is no published clinical trial testing LLLT combined with exosome therapy specifically for hair loss. The theoretical rationale for combining them is reasonable: LLLT increases cellular energy and activates signalling pathways in follicle cells, while exosomes deliver growth factors and microRNA that act on those same cells. The two mechanisms do not conflict, and in principle a more energetically active follicle cell may respond better to exosome-delivered signals.
That said, theoretical synergy is not clinical evidence, and we would not encourage anyone to invest in both simultaneously without a clinical basis for doing so in their specific case. Hair Revive does not offer LLLT, so any combined approach would involve sourcing the device independently. If that is something you want to discuss, a consultation is the right place to do it.
The Bottom Line: Which Treatment is Right for You?
A consultation will look at where you are in your hair loss journey and advise what makes clinical sense for your specific case.
LLLT
You prefer to manage treatment at home rather than attending clinic sessions
You want a lower ongoing cost once the initial device investment is made
Budget is a significant factor
You are not yet on a licensed first-line treatment and want to explore options alongside or instead of minoxidil
You have mild to moderate early-stage pattern hair loss
Exosomes
You prefer clinic-based treatment with professional oversight at each session
You have already tried home treatments without satisfactory results
You want to avoid the long-term home-device adherence commitment
You want the potential for higher per-session density improvements based on the emerging exosome evidence
Neither treatment is the right answer if:
Follicles in the target area have reached full dormancy (a transplant conversation is more appropriate)
You have a scarring alopecia
You have an active scalp infection, malignancy, or uncontrolled inflammatory skin condition in the treatment area
You are pregnant or breastfeeding
You have a medical condition that makes either treatment unsuitable
Is Exosome Hair Restoration Therapy Right For You?
In a world of endless serums, tinctures and procedures it's easy to feel like you're going round in circles.
Exosome Therapy isn't for everybody, and we're upfront about that.
Our 2 Minute Suitability Quiz helps you get a clear picture on whether to proceed with this Treatment or not.
Frequently Asked Questions About LLLT
Not necessarily. LLLT is a specific clinical term for calibrated, low-energy laser light delivered at defined wavelengths (630 to 670 nm red, 800 to 900 nm near-infrared) and energy densities. "Red light therapy" is a consumer umbrella term applied to a wide range of LED panels and handheld devices, most of which do not meet the specifications that the hair loss evidence was built on. If a product describes itself as "red light therapy" without specifying wavelength, power output, and fluence, it is not the same as a clinically evidenced LLLT device.
The evidence was generated across a wide range of device types, from 9-diode laser combs to 272-diode caps. What matters more than diode count is whether the device delivers the right dose (2 to 4 J/cm² fluence) to the treatment area. A high diode count reduces the time needed per session to achieve that dose. A published 2022 meta-analysis found that laser-diode-only devices had a significantly higher effect size than laser/LED combination devices, which is relevant when comparing products.
Yes. The 2022 meta-analysis of FDA-cleared devices found no significant sex difference in treatment response (men SMD 1.40, women SMD 1.36). Most FDA-cleared LLLT devices are indicated for both male and female pattern hair loss.
Initial shedding in the first one to two months is common. Measurable results typically become visible from three to six months, and a full assessment of response is usually made at twelve months. The 2025 meta-analysis found a stronger effect for treatment durations longer than twenty weeks, suggesting sustained use produces better results than short courses.
No. LLLT is not recommended by NICE for hair loss and is not provided on the NHS. It is a self-funded treatment, either by purchasing a home device or by paying for clinic sessions.
No. We specialise in exosome therapy and do not offer LLLT sessions. If after discussing your case we think LLLT is the more appropriate first step, we will say so and help you understand what to look for in a device or a clinic.
No. LED caps emit non-coherent light and typically do not specify wavelength or power output in the way that calibrated laser devices do. The published clinical evidence was generated predominantly with laser-diode devices. Some LED devices may deliver the right parameters, but most consumer LED caps lack the device-specific clinical evidence that FDA-cleared LLLT products have. "LED" and "laser" are not interchangeable terms in this context.
The Best Time To Start Your Hair Restoration Journey? Yesterday.
The second best time? TODAY!
If you're ready to start making meaningful progress towards fuller, thicker hair, then get in touch today.
We are honest and transparent about your potential, and will always set clear expectations, even before you visit us.
So what have you got to lose? Get in touch Today.
Book Online
Call
Text
Visit
Hair Revive at Dr Aesthetica
Unit 1, 1431–1433 Bristol Road South
Birmingham, West Midlands B31 2SU